Pentadeca Arginate

Background

Pentadeca arginate (PDA) is described in commercial and secondary literature as a synthetic pentadecapeptide analog of BPC‑157, modified by incorporation of arginine residues or arginine-rich motifs and sometimes marketed as a “stabilized” or “enhanced” BPC‑157 derivative. However, as of the latest indexed literature, “Pentadeca arginate” or “PDA” is not referenced in PubMed, PMC, or major regulatory or trial registries as a distinct, characterized drug entity, and no peer‑reviewed primary pharmacology, toxicology, or clinical trial publications specific to PDA were identified. Available high‑quality evidence instead concerns the parent peptide BPC‑157 (stable gastric pentadecapeptide), a 15‑amino‑acid peptide originally isolated from human gastric juice and extensively investigated in animal models for cytoprotective and pro‑healing properties.[1][4][9][10][11][15]

Consequently, this entry treats pentadeca arginate as a putative synthetic analog whose purported properties are inferred from and compared to the BPC‑157 evidence base, with explicit acknowledgement that PDA itself lacks peer‑reviewed characterization.

Mechanism of action

Because PDA has not been described in primary literature, its mechanism can only be inferred by analogy to BPC‑157, with substantial uncertainty.

For BPC‑157, multiple mechanistic pathways have been proposed:

• Cytoprotection and endothelial protection: BPC‑157 is described as a “stable gastric pentadecapeptide” that mediates mucosal cytoprotection and systemic organ protection, including gastrointestinal, hepatic, neurologic, and cardiovascular tissues in animal models.[1][4][9][10][11]
• Nitric oxide (NO)–related signaling: Several studies show BPC‑157 interacts with the NO system, counteracting both NO synthase inhibition (e.g. L‑NAME) and NO overproduction (e.g. L‑arginine excess) in diverse rat models, including gastrointestinal injury and ketamine‑induced behavioral disturbances.[1][2][3][4]
  • BPC‑157 modulates eNOS activity and the Src–Caveolin‑1–eNOS pathway in vascular tissues, contributing to vasomotor tone control and thrombo‑resistance.[4]
• Neurotransmitter modulation: A recent review reports that BPC‑157 modulates disturbances in dopamine, serotonin, glutamate, GABA, adrenergic, cholinergic, and NO systems across multiple CNS models (e.g., Parkinson‑like, seizures, traumatic brain injury), suggesting pleiotropic neuromodulatory actions.[8][13]
• Angiogenesis and wound healing: BPC‑157 accelerates healing of muscle, tendon, ligament, bone, and skin in various rat models, with enhanced angiogenesis and collagen organization, although precise receptor targets remain undefined.[9][10][14]
• Anti‑inflammatory and prostaglandin‑system modulation: BPC‑157 reduces NSAID‑induced gastrointestinal and systemic toxicity and modulates prostaglandin interactions, consistent with a broader cytoprotective profile.[1][4][10]

Given these data, a synthetic BPC‑157 analog such as pentadeca arginate is plausibly intended to share similar NO‑modulatory, cytoprotective, and pro‑healing properties, potentially with altered charge, solubility, or stability imparted by arginine‑rich modifications. However, no receptor‑binding, signaling, or pharmacokinetic studies specific to PDA were identifiable, so its precise receptor targets, binding affinities, and downstream signaling remain uncharacterized in the peer‑reviewed literature.

Evidence summary

Preclinical evidence (BPC‑157 as reference)

Evidence for PDA is indirect and extrapolated from BPC‑157, which has extensive animal data:

• Gastrointestinal and multiorgan protection: In a rat short‑bowel model with massive small‑intestine resection, BPC‑157 (10 μg/kg or 10 ng/kg, intraperitoneal) counteracted severe gastrointestinal, liver, and brain lesions and improved survival compared with untreated or diclofenac‑treated controls, in groups of 10–12 rats per condition.[1]
• Cardiovascular system: A comprehensive review of rodent models reports BPC‑157 benefits in myocardial infarction, heart failure, pulmonary hypertension, arrhythmias, and thrombosis, mediated through endothelial protection, collateral circulation activation, and NO-related mechanisms; these summaries pool numerous small in vivo studies (typical n≈6–10 per group).[4]
• Musculoskeletal healing: In rat models of completely severed myotendinous junctions, transected tendons, and ligament injuries, BPC‑157 (systemic or local) improved biomechanical strength and histologic healing relative to controls.[9]
• Wound healing and bleeding: Review of wound‑healing models shows improved cutaneous, muscle, and organ healing, reduced bleeding, and anti‑thrombotic effects; the peptide also circumvents obstructed vessels via rapid recruitment of collateral pathways in rodent studies.[10][14]
• Ophthalmic models: In a glaucoma model where three of four episcleral veins are cauterized, BPC‑157 normalized intraocular pressure and preserved retinal ganglion cells in rats, suggesting neurovascular protection.[7][12]
• Neuropsychiatric and CNS models: In ketamine‑based rat models of “negative‑like” schizophrenia, BPC‑157 ameliorated behavioral deficits and altered brain mRNA expression of Nos1, Nos2, Plcg1, Prkcg, and Ptgs2.[2][3] Broader CNS reviews describe protection in models of traumatic brain injury, spinal cord injury, and neurodegeneration.[8][13]

Pharmacokinetics and disposition (BPC‑157)

A dedicated PK study in rats and dogs demonstrated that BPC‑157 is not degraded in gastric juice, shows measurable systemic exposure after oral and parenteral administration, and is distributed to multiple organs with relatively rapid elimination and peptide‑like metabolism.[5] No such data exist for PDA, and modification with arginine residues could materially alter bioavailability and clearance, but this has not been empirically documented.

Human data

Human data for BPC‑157 itself are limited and largely early‑phase:

• A wound‑healing review notes that BPC‑157 was previously tested in ulcerative colitis and multiple sclerosis clinical trials with no reported toxicity; detailed results, sample sizes, and trial identifiers remain sparsely published.[10][14]
• A recent literature and patent review confirms no serious adverse events reported in the few early human studies and emphasizes the predominance of preclinical data.[11][15]

No indexed human trials, case series, or pharmacology studies specifically involving pentadeca arginate (PDA) were identified in PubMed, PMC, or ClinicalTrials.gov.

Clinical and research uses

Because PDA is not described in the scientific literature, all approved or investigational uses must be inferred cautiously.

For the parent peptide BPC‑157:

• Investigational/experimental indications in animals include:

  • Gastrointestinal protection (e.g., NSAID‑induced lesions, short‑bowel syndrome models).[1][10][14]
  • Cardiovascular injury (myocardial infarction, heart failure, pulmonary hypertension, arrhythmias, thrombosis).[4]
  • Musculoskeletal and soft‑tissue repair (tendon, ligament, muscle, bone, skin).[9][10]
  • CNS and neuropsychiatric disorders (brain trauma, spinal cord injury, ketamine‑induced deficits, seizure models).[2][3][8][13]
  • Ocular diseases (glaucoma and ocular ischemia models).[7][12]

• Human clinical use remains experimental and off‑label, with very limited published trial data; BPC‑157 is not approved as a drug for any indication by FDA or EMA.[10][11][15]

For pentadeca arginate (PDA):

• No documented approved indications, clinical trials, or preclinical efficacy studies were found.
• Any current use appears to be unregulated, off‑label, and unsupported by peer‑reviewed data, often in the context of peptide compounding and performance‑enhancement markets, which are not covered in indexed biomedical literature.

Dosing context

BPC‑157 (reference peptide)

Animal studies employ a wide range of doses and routes:

• Rats, systemic administration: Common doses include 10 μg/kg or 10 ng/kg intraperitoneally in gastrointestinal and multiorgan injury models.[1]
• Oral and local administration: Some models use BPC‑157 delivered in drinking water, orally, or topically at concentrations designed to approximate systemic doses used intraperitoneally, though exact human-equivalent dosing is not established.[9][10]
• Duration: Most studies use acute or short‑term (hours to days) dosing around the time of injury or insult.[1][4][9]

Early human studies (ulcerative colitis, multiple sclerosis) are mentioned qualitatively without detailed dose reports in the accessible reviews.[10][14]

Pentadeca arginate (PDA)

• No peer‑reviewed sources report dose, route, or schedule for PDA in animals or humans.
• Any dosing figures circulating in non‑indexed or commercial contexts cannot be validated against primary literature and should be considered unsubstantiated.

Accordingly, no evidence‑based dosing guidance can be provided for PDA.

Safety profile

BPC‑157

The safety profile of BPC‑157 in preclinical models is generally favorable:

• Reviews state that no LD₁ could be determined in toxicity testing, and no significant systemic toxicity was observed across many rodent studies and the limited human trials.[10][14]
• A recent literature and patent review notes that only a few side effects have been reported following BPC‑157 administration, and these were not severe.[11][15]

However, important limitations apply:

• Most data derive from small animal experiments with short follow‑up.
• Systematic assessment of immunogenicity, carcinogenicity, reproductive toxicity, and long‑term organ toxicity is lacking.[11][15]
• Human data remain sparse, with limited transparency regarding adverse‑event collection and reporting in earlier, unpublished or partially published trials.[10][11]

Pentadeca arginate (PDA)

• No animal or human safety data specific to PDA were identified in indexed literature.
• Structural modification (e.g., arginine substitutions or extensions) can alter immunogenic potential, off‑target binding, and pharmacokinetics, so it is not valid to assume PDA shares the same safety profile as BPC‑157.
• Any claims of safety for PDA currently lack independent scientific verification.

Regulatory status

United States and European Union

For BPC‑157:

• BPC‑157 is not approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) as a medicinal product for any indication, and it does not appear in their approved drug databases.[11][15]
• A recent literature and patent review notes that BPC‑157 was temporarily included on the World Anti‑Doping Agency (WADA) Prohibited List, reflecting concerns about its use in sport rather than formal therapeutic approval.[11][15]

For pentadeca arginate (PDA):

• No entries for “Pentadeca arginate,” “PDA,” or clearly equivalent names were identified in U.S. or EU regulatory databases, nor in ClinicalTrials.gov, indicating no recognized investigational new drug (IND) program or marketing authorization.
• PDA therefore should be regarded as unapproved and experimental, with any clinical use occurring outside formal regulatory frameworks (e.g., as a compounded or gray‑market peptide).

Overall, while BPC‑157 has a substantial preclinical evidence base and limited early human experience, pentadeca arginate remains essentially undocumented in peer‑reviewed science, and extrapolation from BPC‑157 to PDA requires substantial caution.